Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-02-06
2010-11-09
Skelding, Zachary (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
active
07829097
ABSTRACT:
Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1protein within a time period sufficient to protect the organ or tissue from injury.
REFERENCES:
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4554101 (1985-11-01), Hopp
patent: 5013556 (1991-05-01), Woodle et al.
patent: 6811768 (2004-11-01), Zapol et al.
patent: 2003/0060410 (2003-03-01), Tracey et al.
patent: 2004/0136979 (2004-07-01), Bianchi et al.
patent: 2007/0154529 (2007-07-01), Bullerdiek
patent: WO 00/47104 (2000-08-01), None
patent: WO 03/026691 (2003-04-01), None
patent: WO 2004/004763 (2004-01-01), None
patent: WO 2004/061456 (2004-07-01), None
Tsung et al., J. Immunol. 2005;175;7661-7668.
Racanelli et al., Hepatology. Feb. 2006;43(2 Suppl 1):S54-62.
Teoh et al., Hepatology. Jan. 2003;37(1):118-28.
Ueta et al., The Journal of Immunology, 2004, 173: 3337-3347.
Uronen-Hansson et al., Immunology. Feb. 2004;111(2):173-8.
Guillot et al., J Biol Chem. Jan. 23, 2004;279(4):2712-8.
Hornef et al., J Exp Med. Mar. 4, 2002;195(5):559-70.
Kokkola et al., Scand J Immunol. Jan. 2005;61(1):1-9.
Park et al., J Biol Chem. Feb. 27, 2004;279(9):7370-7.
Watanabe et al., Journal of Surgical Research 124, 59-66 (2005).
Muller et al., Journal of Internal Medicine 2004; 255: 332-343.
Ronfani et al., Development 128, 1265-1273 (2001).
Tanaka et al., Pediatr Transplant. Feb. 2005;9(1):47-51.
Zaroff et al., Circulation. Aug. 13, 2002;106(7):836-41.
Abraham et al., “Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation,”The Journal of Immunology, 165(6): 2950-2954 (Sep. 15, 2000).
Andersson et al., “High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes,”J. Exp. Med. 192(4): 565-570 (Aug. 21, 2000).
Bianchi et al., “the DNA Binding Site of HMG1 Protein is Composed of Two Similar Segments (HMG Boxes), Both of Which Have Counterparts in Other Eukaryotic Regulatory Proteins,”The EMBO Journal11(3): 1055-1063 (Mar. 1992).
Cavalieri et al., “Ischemic Preconditioning Attenuates the Oxidant-Dependent Mechanisms of Reperfusion Cell Damage and Death in Rat Liver,”Liver Transplantation, 8(11): 990-999 (Nov. 2002).
Colletti et al., “LPS Pretreatment Protects form Hepatic Ischemia/Reperfusion,”Journal of Surgical Research57(3): 337-343 (Sep. 1994).
Elhage et al., “Differential Effects of Interleukin-! Receptor Antagonist and Tumor Necrosis Factor Binding Protein on Fatty-Streak Formation in Apolipoprotein E-Deficient Mice,”Circulation, 97(3): 242-244 (Jan. 27, 1998).
Epstein et al., “Biological Activity of Liposome-Encapsulated Murine Interferon Υ is Mediated by a Cell Membrane Receptor,”Proceedings of the National Academy of Sciences USA, 82(11): 3688-3692 (Jun. 1985).
Hwang et al., “Hepatic Uptake and Degradation of Unilamellar Sphingomyelin/Cholesterol Liposomes: A Kinetic Study,”Proceedings of the National Academy of Sciences USA, 77(7): 4030-4034 (Jul. 1980).
Ishikawa et al., “Heat Shock Preconditioning on Mitochondria During Warm Ischemia in Rat Livers,”Journal of Surgical Research, 87(2): 178-184 (Dec. 1999).
Kyte et al., “A Simple Method for Displaying the Hydropathic Character of a Protein,”Journal of Molecular Biology, 157(1): 105-115 (May 5, 1982).
Li et al., “Structural Basis for the Proinflammatory Cytokine Activity of High Mobility Group Box 1,”Molecular Medicine, 37-45 (Jan./Feb. 2003).
Martin et al., “Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles,”The Journal of Biological Chemistry, 257(1): 286-288 (Jan. 10, 1982).
Murry et al., “Preconditioning with lschemia: A Delay of Lethal Cell Injury in Ischemic Myocardium,”Circulation, 74(5): 1124-1136 (Nov. 1986).
NCBI, “HMG-1,” Database Entrez-Protein, Accession No. AAA20508 (Aug. 5, 1994). Retrieved on Feb. 14, 2007.
NCBI, “Non-Histone Protein HMG1,” Database Entrez-Protein, Accession No. AAA31050 (Apr. 27, 1993). Retrieved on Feb. 14, 2007.
NCBI, “Amphoterin,” Database Entrez-Protein, Accession No. AAA40729 (Apr. 27, 1993). Retrieved on Feb. 14, 2007.
NCBI, “HMG-1,” Database Entrez-Protein, Accession No. AAA64970 (Apr. 11, 1995). Retrieved on Feb. 14, 2007.
NCBI, “Non-Histone Chromatin Protein HMG1 [Homo Sapiens],” Database Entrez-Protein, Accession No. AAB08987 (Sep. 27, 1996). Retrieved on Feb. 14, 2007.
NCBI, “High Mobility Group Protein [Spalax Ehrenbergi],” Database Entrez-Protein, Accession No. AAC27651 (Jul. 28, 1998). Retrieved on Feb. 14, 2007.
NCBI, “Hypothetical Protein MGC75695 [Xenopus Tropicalis],” Database Entrez-Protein, Accession No. AAH63332 (Jul. 15, 2006). Retrieved on Feb. 14, 2007.
NCBI, “High Mobility Group Box 1 [Rattus Norvegicus],” Database Entrez-Protein, Accession No. AAH88402 (Dec. 2, 2006). Retrieved on Feb. 14, 2007.
NCBI, “HMGB! Protein [Bos Taurus],” Database Entrez-Protein, Accession No. AAI02930 (Jan. 23, 2007). Retrieved on Feb. 14, 2007.
NCBI, “Homo Sapiens High-Mobility Group Box 1 [Synthetic Contruct],” Database Entrez-Protein, Accession No. AAP36330 (May 13, 2003). Retrieved on Feb. 14, 2007.
NCBI, “High-Mobility Group Box 1 [Homo Sapiens],” Database Entrez-Protein, Accession No. AAV38961 (Oct. 28, 2004). Retrieved on Feb. 14, 2007.
NCBI, “High Mobility Group 1 Protein [Gallus Gallus],” Database Entrez-Protein, Accession No. CAA76978 (Apr. 18, 2005). Retrieved on Feb. 14, 2007.
NCBI, “HMGB1 [Homo Sapiens],” Database Entrez-Protein, Accession No. CAG33144 (Apr. 17, 2005). Retrieved on Feb. 14, 2007.
NCBI, “High-Mobility Group Box 1 [Homo Sapiens],” Database Entrez-Protein, Accession No. NP—002119 (Feb. 4, 2007). Retrieved on Feb. 14, 2007.
NCBI, “High Mobility Group Protein 1 (HMG-1) (Amphoterin) (Heparin-binding protein p30),” Database Entrez-Protein, Accession No. P07155 (Oct. 1, 2004). Retrieved on Feb. 14, 2007.
NCBI, “High Mobility Group Protein B1 (High Mobility Group Protein 1) (HMG-1),” Database Entrez-Protein, Accession No. P09429 (Jan. 23, 2007). Retrieved on Feb. 14, 2007.
NCBI, “Nonhistone Chromosomal Protein HMG-1—Human,” Database Entrez-Protein, Accession No. S29857 (Jul. 23, 1999). Retrieved on Feb. 14, 2007.
NCBI, “Predicted: Similar to High Mobility Group Protein 1 (HMG-1) (High Mobility Group Protein B1) (Amphoterin) (Heparin-Binding Protein p30) Isoform 1 [Mus Musculus],” Database Entrez-Protein, Accession No. XP—484795 (Jan. 11, 2006). Retrieved on Feb. 14, 2007.
NCBI, “Predicted: Similar to High Mobility Group Box 1; High Mobility Group Protein 1 [Pan Troglodytes],” Database Entrez-Protein, Accession No. XP—516325 (Nov. 9, 2004).
Shohami et al., “Cytokine Production in the Brain Following Closed Head Injury: Dexanabinlo (HU-211) is a Novel TNF-α Inhibitor and an Effective Neuroprotectant,”Journal of Neuroimmunology, 72(2): 169-177 (Feb. 1997).
Terregino et al. “Endogenous Mediators in Emergency Department Patients With Presumed Sepsis: Are Levels Associated With Progression to Severe Sepsis and Death,”Annals of Emergency Medicine, 35(1): 26-34 (Jan. 2000).
Tsai et al., “Preconditioning: Evolution of Basic Mechanisms to Potential Therapeutic Strategies,”Shock, 21(3): 195-209 (Mar. 2004.
Tsung et al., “The Nuclear Factor HMGB1 Mediates Hepatic Injury After Murine Liver Ischemia-Reperfusion,”The Journal of Experimental Medicine, 201(7): 1135-1143 (Apr. 4, 2005).
Wang et al., “HMG-1 as a Late Mediator of Endotoxin Lethality in Mice,”Science, 285: 248-251 (Jul. 9, 1999).
Yang et al., “Reversing Established Sepsis with Antagonists
Billiar Timothy R.
Fink Mitchell P.
Tracey Kevin J.
Tsung Allan
Leydig , Voit & Mayer, Ltd.
Skelding Zachary
The Feinstein Institute for Medical Research
University of Pittsburgh - Of the Commonwealth System of Higher
LandOfFree
Use of HMGB1 for protection against ischemia reperfusion injury does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of HMGB1 for protection against ischemia reperfusion injury, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of HMGB1 for protection against ischemia reperfusion injury will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4207204